Arieli A, Dicken U, Dagoni I, Spirer Y, Zamwel S
The Hebrew University of Jerusalem, Faculty of Agricultural, Food and Environmental Quality Sciences, Rehovot 76100, Israel.
J Dairy Sci. 2008 May;91(5):1845-51. doi: 10.3168/jds.2007-0795.
The object of this study was to evaluate the impact of monensin administration on the early lactation performance of cows maintained on a high-energy diet, and on health traits during the transition period. Cows (n = 168; parity 3.3 +/- 1.4, initial body condition score 3.1 +/- 0.08, and milk yield of 34.3 kg/d +/- 0.9 for multiparous cows in the preceding lactation) were divided into control and monensin treatment groups. A controlled-release capsule supplying 335 mg of monensin/d for 95 d was inserted into the rumen of monensin-treated cows 30 d before the expected calving. Blood samples were obtained 2 h after feeding on d 14 prepartum and on d 7, 14, and 50 postpartum. Plasma glucose concentration was 3% higher (58 +/- 0.5 vs. 56.4 +/- 0.5 mg/dL) and beta-hydroxybutyric acid was 17% (6.7 +/- 0.3 vs. 8.0 +/- 0.3 mg/dL) lower in monensin-treated than control cows. Plasma glucose was 10% higher (60.0 +/- 0.6 vs. 54.5 +/- 0.3 mg/dL) and beta-hydroxybutyric acid was 16% lower (6.8 +/- 0.3 vs. 7.9 +/- 0.2 mg/dL) in primiparous than multiparous cows. Plasma nonesterified fatty acid concentration (measured only in primiparous cows) was 17% lower (287 +/- 15 vs. 336 +/- 17 muEq/L) in treated than in control cows. Rate of ketosis incidence was 60% lower (8 vs. 21%) in monensin-treated than in control cows, and the proportion of control cows that required a supply of glucogenic precursors was 3-fold higher than in monensin-treated cows. The body condition score was 3.1 +/- 0.05, 2.7 +/- 0.05, and 2.4 +/- 0.05 on d 60 prepartum and d 7 and 50 postpartum, respectively, and was not affected by treatment. During the first 5 mo of lactation, milk yield was 7% higher (37.6 +/- 0.6 vs. 35.2 +/- 0.6 kg/d) in monensin-treated cows than in control cows. Our results showed that monensin administration, as a controlled-release capsule in prepartum cows, can be beneficial, even if these cows are maintained on a high-energy diet during the subsequent lactation.
本研究的目的是评估莫能菌素给药对维持高能日粮奶牛早期泌乳性能以及围产期健康性状的影响。奶牛(n = 168;胎次3.3±1.4,初始体况评分3.1±0.08,前一胎次经产奶牛日产奶量34.3 kg/d±0.9)被分为对照组和莫能菌素处理组。在预期产犊前30天,将一个持续释放胶囊插入莫能菌素处理组奶牛的瘤胃中,该胶囊每天提供335 mg莫能菌素,持续95天。在产前14天、产后7天、14天和50天的饲喂后2小时采集血样。与对照组奶牛相比,莫能菌素处理组奶牛的血浆葡萄糖浓度高3%(58±0.5对56.4±0.5 mg/dL),β-羟基丁酸低17%(6.7±0.3对8.0±0.3 mg/dL)。初产奶牛的血浆葡萄糖高10%(60.0±0.6对54.5±0.3 mg/dL),β-羟基丁酸低16%(6.8±0.3对7.9±0.2 mg/dL)。与对照组奶牛相比,处理组奶牛(仅对初产奶牛进行测量)的血浆非酯化脂肪酸浓度低17%(287±15对336±17 μEq/L)。莫能菌素处理组奶牛的酮病发生率比对照组低60%(8%对21%),对照组中需要补充生糖前体的奶牛比例比莫能菌素处理组高3倍。产前60天、产后7天和50天的体况评分分别为3.1±0.05、2.7±0.05和2.4±0.05,且不受处理影响。在泌乳的前5个月,莫能菌素处理组奶牛的产奶量比对照组高7%(37.6±0.6对35.2±0.6 kg/d)。我们的结果表明,在产前奶牛中以持续释放胶囊形式给药莫能菌素可能是有益的,即使这些奶牛在随后的泌乳期维持高能日粮。